PDCD1 and neoplasm: We profiled our series of 44 tumor samples that we coupled with 118 profiled samples from four published public datasets [15, 23, 32, 33], obtaining a cohort of 162 advanced NSCLC patients treated with anti-PD1/PDL1 ICI.